EMBC | Embecta Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	15.99 - 16.59
52 Week Range	9.93 - 19.79
Beta	0.96
Implied Volatility	92.24%
IV Rank	27.21%
Day's Volume	345,811
Average Volume	415,482
Shares Outstanding	57,701,830
Market Cap	950,349,140
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2022-03-22

Valuation
Profitability
Growth
Health
P/E Ratio	13.73
Forward P/E Ratio	5.95
EPS	1.20
1YR Price Target	29.00
Dividend Yield	3.75%
Dividend Per Share	0.62
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2,200
Country	USA
Website	EMBC

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

EMBC's peers: ALC, BAX, ISRG, RMD, WST, COO, ICUI, MMSI, ANGO, ATR, TFX, HAE, NVST, AKYA, ATRC, ATRI

*Chart delayed

Analyzing fundamentals for EMBC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see EMBC Fundamentals page.

Watching at EMBC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on EMBC Technicals page.